Cantargia
Develops antibody therapies targeting IL1RAP for cancer and inflammatory diseases.
CANTA | ST
Overview
Corporate Details
- ISIN(s):
- SE0006371126 (+3 more)
- LEI:
- 549300GKWRT7RXI4VS85
- Country:
- Sweden
- Address:
- Scheelevägen 27, 223 63 Lund
- Website:
- https://cantargia.com/en/
- Sector:
- Manufacturing
Description
Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-12-02 11:00 |
Extraordinary general meeting in Cantargia AB (publ)
|
English | 90.7 KB | ||
| 2024-12-02 11:00 |
Extra bolagsstämma i Cantargia AB (publ)
|
Swedish | 91.1 KB | ||
| 2024-11-29 13:25 |
Cantargia expands the CAN10 phase 1 clinical program building on positive resul…
|
English | 104.6 KB | ||
| 2024-11-29 13:25 |
Cantargia utökar CAN10:s fas I kliniska program baserat på positiva resultat
|
Swedish | 105.9 KB | ||
| 2024-11-15 07:00 | English | 3.4 MB | |||
| 2024-11-13 11:00 |
Cantargia presents Nomination Committee ahead of 2025 AGM
|
English | 93.9 KB | ||
| 2024-11-07 10:14 | English | 35.5 KB | |||
| 2024-11-06 18:03 |
Notice of extraordinary general meeting in Cantargia AB (publ)
|
English | 111.7 KB | ||
| 2024-11-06 18:00 |
Cantargia resolves on a rights issue of approximately SEK 170 million
|
English | 142.4 KB | ||
| 2024-10-28 14:45 |
Cantargia reports new results from clinical studies investigating nadunolimab i…
|
English | 110.9 KB | ||
| 2024-10-11 11:50 |
Cantargia reports new positive results on biomarkers and safety in CAN10 phase …
|
English | 108.7 KB | ||
| 2024-09-30 13:30 |
Cantargia rapporterar start av upprepad dosering i fas I klinisk studie av CAN10
|
Swedish | 106.3 KB | ||
| 2024-09-25 07:00 |
Cantargia presenterar nya resultat på EADV 2024 som visar potentialen av CAN10-…
|
Swedish | 107.8 KB | ||
| 2024-09-25 07:00 |
Cantargia presents new results at EADV 2024 highlighting the potential of CAN10…
|
English | 106.7 KB | ||
| 2024-09-14 09:00 |
Cantargia presenterar positiva resultat på ESMO Congress 2024 av nadunolimab ko…
|
Swedish | 112.5 KB |
Automate Your Workflow. Get a real-time feed of all Cantargia filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cantargia
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cantargia via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-19 | Nedjad Losic | Other | Buy | 21,375 | 33,131.25 SEK |
| 2025-01-02 | Antonius Franciscus Berkien | Other | Other | 21,621 | 39,998.85 SEK |
| 2024-12-20 | Göran Forsberg | Other | Other | 152,206 | 281,581.10 SEK |
| 2024-12-20 | Nedjad Losic | Other | Other | 12,875 | 23,818.75 SEK |
| 2024-12-09 | Antonius Franciscus Berkien | Other | Buy | 3,741 | 6,733.80 SEK |
| 2023-01-19 | Nedjad Losic | Other | Buy | 3,918 | 29,110.74 SEK |
| 2023-01-17 | Göran Forsberg | Other | Buy | 17,000 | 140,250.00 SEK |
| 2023-01-17 | Bengt Jöndell | Other | Buy | 6,500 | 54,665.00 SEK |
| 2022-07-28 | Göran Forsberg | Other | Other | 91,765 | 344,118.75 SEK |
| 2022-07-28 | Thoas Fioretos | Other | Other | 78,400 | 294,000.00 SEK |
Peer Companies
